anti-mutant calreticulin monoclonal antibody INCA033989
Term · Oncology and biomedicine · MLC-T-ONC-010910
A human immunoglobulin G1 (IgG1) monoclonal antibody targeting the mutated form of calreticulin (mutCALR), with potential antineoplastic activity. Upon administration, anti-mutCALR monoclonal antibody INCA033989 selectively targets and binds to mutCALR expressed on CALR mutated CD34-positive hematopoietic stem cells (HSCs) while not binding to normal wild-type (WT) CALR on healthy CD34-positive HSCs. This prevents the formation of a mutCALR complex with the thrombopoietin receptor (TPO-R) in the endoplasmic reticulum (ER), prevents the CALR mutant-dependent TPO-R dimerization and suppresses TPO-R signaling. This prevents the activation of the downstream Janus kinase 2 (JAK2)/signal transducer and activator of transcription (STAT) signaling pathway. This prevents mutCALR-driven oncogenic cell proliferation, causes cell cycle arrest and induces cell death. CALR mutations, either insertions or deletions in exon 9, result in a frameshift that causes the loss of the KDEL ER retention motif. CALR mutations drive a variety of myeloproliferative neoplasms (MPNs).
| Identifier | MLC-T-ONC-010910 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-mutant CALR monoclonal antibody INCA033989; anti-mutCALR monoclonal antibody INCA033989 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010910",
"term": "anti-mutant calreticulin monoclonal antibody INCA033989",
"field": "Oncology and biomedicine",
"definition": "A human immunoglobulin G1 (IgG1) monoclonal antibody targeting the mutated form of calreticulin (mutCALR), with potential antineoplastic activity. Upon administration, anti-mutCALR monoclonal antibody INCA033989 selectively targets and binds to mutCALR expressed on CALR mutated CD34-positive hematopoietic stem cells (HSCs) while not binding to normal wild-type (WT) CALR on healthy CD34-positive HSCs. This prevents the formation of a mutCALR complex with the thrombopoietin receptor (TPO-R) in the endoplasmic reticulum (ER), prevents the CALR mutant-dependent TPO-R dimerization and suppresses TPO-R signaling. This prevents the activation of the downstream Janus kinase 2 (JAK2)/signal transducer and activator of transcription (STAT) signaling pathway. This prevents mutCALR-driven oncogenic cell proliferation, causes cell cycle arrest and induces cell death. CALR mutations, either insertions or deletions in exon 9, result in a frameshift that causes the loss of the KDEL ER retention motif. CALR mutations drive a variety of myeloproliferative neoplasms (MPNs).",
"synonyms": [
"anti-mutant CALR monoclonal antibody INCA033989",
"anti-mutCALR monoclonal antibody INCA033989"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-mutant-calreticulin-monoclonal-antibody-inca033989/"
}
Record 2,034 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.